Immunotherapy with daratumumab safe and active in relapsed ALL and LL (Bhatla et al., 2024) Immunotherapy with daratumumab is safe for children with relapsed acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL) in whom standard chemotherapy fails.
Cause and biomarker high-risk lymphoma found (Kroeze et al., 2024) Researchers from the Princess Máxima Center have found the most common cause of recurrent T-cell lymphoblastic lymphoma (T-LBL).
Potential benefit CAR T-cell therapy in B-cell non-Hodgkin lymphoma (Minard-Colin et al., 2022) Treatment with tisagenlecleucel may be of benefit to a proportion of children and young adults with B-cell non-Hodgkin's lymphoma (B-NHL) in whom the disease has recurred or failed to respond to previous treatment.
New immunotherapy cures more children with lymphoma (Minard-Colin et al., 2020) A new combination treatment consisting of chemotherapy and the drug rituximab can cure a significant proportion of patients with B-cell non-Hodgkin lymphoma.
Checkpoint inhibitors in the treatment of pediatric solid tumors (Geoerger et al., 2020) In this study researchers determined whether the drug atezolizumab, a so-called checkpoint inhibitor, was active and safe to use in children with solid tumors, including lymphoma.